Dianomi Therapeutics, a biohealth company focused on osteoarthritis and pain with technology, has received a $3 million investment from its new partner, Ligand Pharmaceuticals, the company announced recently.

According to a release, the partnership focuses on Dianomi’s proprietary Mineral Coated Microparticle (MCM) technology, which mimics the ability of human bones and teeth to store and protect biologics, potentially leading to lower dosing and enhance patient compliance.

“Murphy’s lab has honed the MCM technology over the last decade, enabling Dianomi to quickly move forward with product development opportunities to aid patients with osteoarthritis and pain,” Dianomi CEO Barry Kurokawa said in a statement. “Our proprietary technology provides the opportunity to breathe new life into products that are looking at impending patent expiration or experience increased competition, thus providing next-generation treatment options.”

The company’s technology is licensed through the Wisconsin Alumni Research Foundation.